Current use and future development of gemtuzumab ozogamicin

Seminars in Hematology

Volumn 38, Issue 3 SUPPL. 6, 2001, Pages 24-31

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINOTRANSFERASE; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEVER; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASIA; NAUSEA; PAIN; PRIORITY JOURNAL; REVIEW; RIGOR;

EID: 0034884092     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2001.24263     Document Type: Review

References (16)

1. Intensive postremission chemotherapy in adults with acute myeloid leukemia
2. Management of acute myeloid leukemia in elderly patients
3. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
4. Expression of normal myeloid-associated antigens by acute leukemia cells
5. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
6. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
7. Localization of radiolabeled antimyeloid antibodies in human acute leukemia xenograft tumor model
8. I
9. I and DNA: Molecular recognition process responsible for site specificity
10. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
11. Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse
12. Efficacy and safety of CMA-676 in patients with AML in first relapse
13. Preliminary report of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients ≥ 60 years of age with acute myelogenous leukemia in first relapse
14. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients < 60 and ≥ 60 years of age with AML in first relapse
15. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse
16. Mini-allografts: Ongoing trials in humans